Pay in 4 interest-free payments of $6.07 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
A Phase 2 trial published in the New England Journal of Medicine (2023) reported significant weight reduction with retatrutide over 48 weeks, and further trials are registered on ClinicalTrials
BPC-157 Research Grade Laboratory Standard BPC-157 research grade peptide is prepared under catalog standards to support non-clinical laboratory research
In STEP 1, 69% of participants reached this milestone
doi: 10.1111/dom.12885 Summary Keywords lipodystrophy, glucagon-like peptide-1, diabetes, seipin, liraglutide Citation Roumane A, Mcilroy GD, Sommer N, Han W, Heisler LK and Rochford JJ (2024) GLP-1 receptor agonist improves metabolic disease in a pre-clinical model of lipodystrophy
PMC 5405617
Statements Ethics statement The study was performed in accordance with the Declaration of Helsinki and a written consent was obtained from both the patient and his caretaker authorizing the publication of the clinical case report
